These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 36936968)
1. Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections. Yang J; Won G; Baek JY; Lee YH; Kim H; Huh K; Cho SY; Kang CI; Chung DR; Peck KR; Lee KW; Park JB; Yoon SE; Kim SJ; Kim WS; Yim MS; Kim K; Hyeon S; Kim BC; Lee YK; Ko JH Front Immunol; 2023; 14():1139980. PubMed ID: 36936968 [TBL] [Abstract][Full Text] [Related]
2. Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023. Yang J; Hyeon S; Baek JY; Kang MS; Lee KY; Lee YH; Huh K; Cho SY; Kang CI; Chung DR; Peck KR; Won G; Lee HW; Kim K; Hwang I; Lee SY; Kim BC; Lee YK; Ko JH J Korean Med Sci; 2023 Jul; 38(27):e205. PubMed ID: 37431539 [TBL] [Abstract][Full Text] [Related]
9. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment. Focosi D; Casadevall A Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis. Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R Transpl Int; 2024; 37():12061. PubMed ID: 38328617 [TBL] [Abstract][Full Text] [Related]
11. Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. Benotmane I; Velay A; Gautier-Vargas G; Olagne J; Obrecht A; Cognard N; Heibel F; Braun-Parvez L; Keller N; Martzloff J; Perrin P; Pszczolinski R; Moulin B; Fafi-Kremer S; Thaunat O; Caillard S Am J Transplant; 2022 Nov; 22(11):2675-2681. PubMed ID: 35713984 [TBL] [Abstract][Full Text] [Related]
12. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916 [TBL] [Abstract][Full Text] [Related]
13. Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients. Moal V; Valade M; Boschi C; Robert T; Orain N; Bancod A; Edouard S; Colson P; La Scola B Front Microbiol; 2023; 14():1147455. PubMed ID: 37065151 [TBL] [Abstract][Full Text] [Related]
15. Longitudinal kinetics of neutralizing antibodies against circulating SARS-CoV-2 variants and estimated level of group immunity of booster-vaccinated individuals during omicron-dominated COVID-19 outbreaks in the Republic of Korea, 2022. Lee YJ; Choi JY; Yang J; Baek JY; Kim HJ; Kim SH; Jeong H; Kim MS; Lee HW; Kang G; Chung EJ; Kim TY; Hong HJ; Lee SE; Jang YG; Kim SS; Peck KR; Ko JH; Kim B Microbiol Spectr; 2023 Sep; 11(5):e0165523. PubMed ID: 37750684 [TBL] [Abstract][Full Text] [Related]
16. Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections. Dichtl S; Zaderer V; Kozubowski V; Abd El Halim H; Lafon E; Lanser L; Weiss G; Lass-Flörl C; Wilflingseder D; Posch W Front Med (Lausanne); 2022; 9():1005589. PubMed ID: 36250084 [TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158 [TBL] [Abstract][Full Text] [Related]
18. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period. Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL Front Immunol; 2023; 14():1259725. PubMed ID: 37928549 [TBL] [Abstract][Full Text] [Related]
19. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan. Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience. Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]